autologous glioma tumor cell lysates (inactivated) (SITOIGANAP)

Quick answer

autologous glioma tumor cell lysates (inactivated) (SITOIGANAP) is an FDA-listed pharmaceutical active ingredient.

Key facts

INN autologous glioma tumor cell lysates (inactivated)

Brand SITOIGANAP

ATC code L01XX

Frequently asked questions

What is autologous glioma tumor cell lysates (inactivated)?

autologous glioma tumor cell lysates (inactivated) (SITOIGANAP) is an FDA-listed pharmaceutical active ingredient.

What is the brand name for autologous glioma tumor cell lysates (inactivated)?

SITOIGANAP is a marketed brand name for autologous glioma tumor cell lysates (inactivated). Check FDA Drugs@FDA for the current US label holder and prescribing information.

Data sources & disclaimer

This profile compiles public regulatory and patent records for informational use by pharmaceutical professionals. It is not medical advice, not investment advice, and not an official FDA, EMA, USPTO, SEC, or NIH record. NovaPharmaNews does not represent any manufacturer, sponsor, or regulator unless explicitly stated in a separate agreement.

Patent expiry and loss-of-exclusivity dates may be estimates when derived from grant date or bulk patent metadata. Confirm material dates against the USPTO, FDA Orange Book, or counsel before contractual or regulatory decisions.

Verify critical facts using the primary sources below. See our data sources policy (methodology) and privacy policy.

Last data refresh: May 26, 2026

News by Topic

Press Releases

Analysis by Topic

Whitepapers

Browse

By Region

Entities

Explore

Directory

By Region

For Suppliers

For Brands

Resources

Popular Topics

More Topics

Browse

Calculators

QA / Regulatory

Reference

About Us

Get in Touch

Quick Actions

Recent Searches

Popular Topics

Suggestions

autologous glioma tumor cell lysates (inactivated)

Quick answer

Key facts

Frequently asked questions